MedPath

Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Survival

Completed
Conditions
Coronary Artery Disease
Interventions
Other: No intervention will take place for this retrospective and observational study.
Registration Number
NCT03417050
Lead Sponsor
Erasmus Medical Center
Brief Summary

An investigator-driven, retrospective study to compare long-term survival-data (10-year follow-up) of patients with coronary artery disease (CAD), previously enrolled in the SYNTAX trial, who were randomized to percutaneous coronary intervention (PCI) using a paclitaxel (TAXUS) drug-eluting-stent (DES) or coronary artery bypass grafting (CABG).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2636
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Randomized CABG patientsNo intervention will take place for this retrospective and observational study.Patients which were randomized to undergo CABG.
Registry PCINo intervention will take place for this retrospective and observational study.Patients for whom only one treatment option was suitable were included into a parallel, nested registry: the PCI registry for CABG-ineligible patients.
Randomized PCI patientsNo intervention will take place for this retrospective and observational study.Patients which were randomized to undergo PCI.
Registry CABGNo intervention will take place for this retrospective and observational study.Patients for whom only one treatment option was suitable were included into a parallel, nested registry: the CABG registry for PCI-ineligible patients.
Primary Outcome Measures
NameTimeMethod
Long-term survival status10-year

All-cause death

Secondary Outcome Measures
NameTimeMethod
Cause of death10-year

Cause-specific death, separated in cardiovascular and non-cardiovascular death with specific causes for cardiovascular deaths.

© Copyright 2025. All Rights Reserved by MedPath